ECSP18000042A - Compuestos inhibidores de la señalización de la vía de notch - Google Patents
Compuestos inhibidores de la señalización de la vía de notchInfo
- Publication number
- ECSP18000042A ECSP18000042A ECIEPI201842A ECPI201800042A ECSP18000042A EC SP18000042 A ECSP18000042 A EC SP18000042A EC IEPI201842 A ECIEPI201842 A EC IEPI201842A EC PI201800042 A ECPI201800042 A EC PI201800042A EC SP18000042 A ECSP18000042 A EC SP18000042A
- Authority
- EC
- Ecuador
- Prior art keywords
- notch
- inhibiting compounds
- way signaling
- pharmaceutically acceptable
- signaling inhibiting
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 230000011664 signaling Effects 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title 1
- 210000002266 hair cells auditory Anatomy 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 206010011891 Deafness neurosensory Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000005650 Notch Receptors Human genes 0.000 abstract 1
- 108010070047 Notch Receptors Proteins 0.000 abstract 1
- 208000009966 Sensorineural Hearing Loss Diseases 0.000 abstract 1
- 230000006698 induction Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 231100000879 sensorineural hearing loss Toxicity 0.000 abstract 1
- 208000023573 sensorineural hearing loss disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente invención proporciona compuestos, o una sal farmacéuticamente aceptable de estos, y una composición farmacéutica que contiene dichos compuestos o una sal farmacéuticamente aceptable de esta, útil como un inhibidor de la señalización de la vía Notch para los cánceres nombrados, pérdida de audición neurosensorial causada por la pérdida de células ciliadas auditivas, e inducción de la generación de células ciliadas auditivas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562189393P | 2015-07-07 | 2015-07-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP18000042A true ECSP18000042A (es) | 2018-03-31 |
Family
ID=56507825
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECIEPI201842A ECSP18000042A (es) | 2015-07-07 | 2018-01-02 | Compuestos inhibidores de la señalización de la vía de notch |
Country Status (42)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1211875A1 (en) | 2012-09-07 | 2016-06-03 | Massachusetts Eye & Ear Infirmary | Treating hearing loss |
| JO3491B1 (ar) | 2015-07-07 | 2020-07-05 | Audion Therapeutics | مركبات مثبطة لإشارات مسار notch |
| US11185536B2 (en) | 2015-12-04 | 2021-11-30 | Massachusetts Eye And Ear Infirmary | Treatment of hearing loss by inhibition of casein kinase 1 |
| JP7033789B2 (ja) | 2016-06-29 | 2022-03-11 | オトノミー，インク． | トリグリセリド耳用製剤とその使用 |
| US11253193B2 (en) * | 2016-11-08 | 2022-02-22 | Cochlear Limited | Utilization of vocal acoustic biomarkers for assistive listening device utilization |
| JP6904612B2 (ja) | 2016-12-16 | 2021-07-21 | パイプライン セラピューティクス， インコーポレイテッド | 蝸牛シナプス障害を処置する方法 |
| CN110461835A (zh) * | 2017-03-24 | 2019-11-15 | 诺华股份有限公司 | 异噁唑甲酰胺化合物及其用途 |
| WO2020016855A1 (en) * | 2018-07-20 | 2020-01-23 | The Hong Kong Polytechnic University | Peptides for specific inhibition of jag1-notch1 pathway |
| MX2021003294A (es) * | 2018-09-21 | 2021-07-15 | Novartis Ag | Compuestos de isoxazol carboxamida y usos de los mismos. |
| EP3860562A1 (en) | 2018-10-02 | 2021-08-11 | Frequency Therapeutics, Inc. | Pharmaceutical compositions comprising otic therapeutic agents and related methods |
| US20220008433A1 (en) * | 2018-11-30 | 2022-01-13 | Massachusetts Eye And Ear Infirmary | Inhibition of Lysine Demethylase 1 (Lsd1) Induces Differentiation of Hair Cells |
| SG11202111191YA (en) | 2019-04-08 | 2021-11-29 | Frequency Therapeutics Inc | Combination of chir99021 and valproic acid for treating hearing loss |
| WO2021150672A2 (en) * | 2020-01-22 | 2021-07-29 | Beth Israel Deaconess Medical Center, Inc. | Biomarkers for placenta accreta spectrum (pas) disorders |
| WO2022158610A1 (en) * | 2021-01-20 | 2022-07-28 | Prism BioLab Co., Ltd. | Novel bicyclic compounds |
| JP2025512138A (ja) * | 2022-04-11 | 2025-04-16 | 株式会社 PRISM BioLab | 新規七員環縮合化合物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8673634B2 (en) | 2003-11-13 | 2014-03-18 | Massachusetts Eye & Ear Infirmary | Method for the treatment of hearing loss |
| KR101169628B1 (ko) | 2006-03-27 | 2012-07-30 | 에프. 호프만-라 로슈 아게 | 감마 세크레테아제 저해제로서의 말론아미드 유도체 |
| AU2009212135B2 (en) | 2008-02-07 | 2014-08-21 | Massachusetts Eye & Ear Infirmary | Compounds that enhance Atoh-1 expression |
| US8648119B2 (en) | 2008-05-23 | 2014-02-11 | Otonomy, Inc. | Controlled release immunomodulator compositions and methods for the treatment of otic disorders |
| CA2743436C (en) | 2008-11-24 | 2017-10-31 | Massachusetts Eye & Ear Infirmary | Pathways to generate hair cells |
| WO2012047706A2 (en) | 2010-10-06 | 2012-04-12 | Massachusetts Eye & Ear Infirmary | Methods for promotiing reinnervation of auditory hair cells |
| JO3148B1 (ar) * | 2011-07-27 | 2017-09-20 | Lilly Co Eli | مركب مثبط لإشارات مسار notch |
| US8716229B2 (en) | 2011-11-09 | 2014-05-06 | Massachusetts Eye & Ear Infirmary | Osteoprotegerin in neuroprotection |
| HK1211875A1 (en) * | 2012-09-07 | 2016-06-03 | Massachusetts Eye & Ear Infirmary | Treating hearing loss |
| WO2014071275A1 (en) | 2012-11-02 | 2014-05-08 | Genesys Research Institute | Compositions and methods for auditory therapy |
| JO3491B1 (ar) | 2015-07-07 | 2020-07-05 | Audion Therapeutics | مركبات مثبطة لإشارات مسار notch |
| JP6904612B2 (ja) * | 2016-12-16 | 2021-07-21 | パイプライン セラピューティクス， インコーポレイテッド | 蝸牛シナプス障害を処置する方法 |
-
2016
- 2016-06-21 JO JOP/2016/0125A patent/JO3491B1/ar active
- 2016-06-21 TW TW105119456A patent/TWI625332B/zh active
- 2016-06-21 AR ARP160101848A patent/AR105080A1/es active IP Right Grant
- 2016-07-01 DK DK16741742.7T patent/DK3319967T3/da active
- 2016-07-01 TR TR2019/08683T patent/TR201908683T4/tr unknown
- 2016-07-01 NZ NZ737322A patent/NZ737322A/en unknown
- 2016-07-01 MA MA42399A patent/MA42399B1/fr unknown
- 2016-07-01 HU HUE16741742 patent/HUE044666T2/hu unknown
- 2016-07-01 WO PCT/US2016/040612 patent/WO2017007702A1/en not_active Ceased
- 2016-07-01 UA UAA201712094A patent/UA120539C2/uk unknown
- 2016-07-01 LT LTEP16741742.7T patent/LT3319967T/lt unknown
- 2016-07-01 CA CA2987431A patent/CA2987431C/en active Active
- 2016-07-01 EA EA201792478A patent/EA032634B1/ru not_active IP Right Cessation
- 2016-07-01 RS RS20190820A patent/RS59115B1/sr unknown
- 2016-07-01 US US15/736,345 patent/US10450317B2/en active Active
- 2016-07-01 HK HK18106380.5A patent/HK1247187B/en unknown
- 2016-07-01 SI SI201630270T patent/SI3319967T1/sl unknown
- 2016-07-01 HR HRP20191175TT patent/HRP20191175T1/hr unknown
- 2016-07-01 PT PT16741742T patent/PT3319967T/pt unknown
- 2016-07-01 MD MDE20180506 patent/MD3319967T2/ro unknown
- 2016-07-01 PE PE2018000012A patent/PE20180412A1/es unknown
- 2016-07-01 CN CN201680039699.XA patent/CN107849054B/zh active Active
- 2016-07-01 KR KR1020187000149A patent/KR102078946B1/ko active Active
- 2016-07-01 EP EP16741742.7A patent/EP3319967B1/en active Active
- 2016-07-01 PL PL16741742T patent/PL3319967T3/pl unknown
- 2016-07-01 CR CR20220368A patent/CR20220368A/es unknown
- 2016-07-01 AU AU2016289822A patent/AU2016289822B2/en active Active
- 2016-07-01 TN TNP/2017/000495A patent/TN2017000495A1/en unknown
- 2016-07-01 MY MYPI2018700032A patent/MY197519A/en unknown
- 2016-07-01 CR CR20170598A patent/CR20170598A/es unknown
- 2016-07-01 JP JP2017568395A patent/JP6571214B2/ja active Active
- 2016-07-01 ES ES16741742T patent/ES2735139T3/es active Active
- 2016-07-01 MX MX2017016555A patent/MX376082B/es active IP Right Grant
- 2016-07-01 ME MEP-2019-191A patent/ME03495B/me unknown
-
2017
- 2017-11-16 IL IL255726A patent/IL255726B/en active IP Right Grant
- 2017-11-20 ZA ZA2017/07858A patent/ZA201707858B/en unknown
- 2017-12-20 SV SV2017005597A patent/SV2017005597A/es unknown
-
2018
- 2018-01-02 CL CL2018000007A patent/CL2018000007A1/es unknown
- 2018-01-02 EC ECIEPI201842A patent/ECSP18000042A/es unknown
- 2018-01-05 PH PH12018500047A patent/PH12018500047B1/en unknown
- 2018-01-05 DO DO2018000005A patent/DOP2018000005A/es unknown
- 2018-01-12 CO CONC2018/0000224A patent/CO2018000224A2/es unknown
-
2019
- 2019-07-23 CY CY20191100776T patent/CY1122024T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP18000042A (es) | Compuestos inhibidores de la señalización de la vía de notch | |
| DOP2020000102A (es) | Compuestos útiles para inhibir a cdk7 | |
| SV2018005794A (es) | Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos | |
| CO2019007839A2 (es) | Composiciones y métodos para inhibir la acción de la arginasa | |
| CO2018004750A2 (es) | Composiciones para inhibir la actividad arginasa | |
| MX392031B (es) | Compuestos y métodos para modular la cinasa de linfocitos t inducible por interleucina 2 | |
| SV2016005180A (es) | Amino-heteroaril-benzamidas como inhibidores de cinasa | |
| GT201700189A (es) | Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos | |
| MX2017006266A (es) | Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1(irak) y sus usos. | |
| ECSP17054980A (es) | Inhibidores selectivos de bace1 | |
| MX2016010524A (es) | Derivados de piridazina para uso en la prevencion o tratamiento de trastorno ataxico. | |
| CL2018001067A1 (es) | Compuesto piranodipiridínico. | |
| MX2019010330A (es) | Formulaciones con mejora de la estabilidad. | |
| MX2016015106A (es) | Derivados de dipicolilamina y sus usos farmaceuticos. | |
| CL2018000489A1 (es) | Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona | |
| EA201791596A1 (ru) | Пиразоловые соединения | |
| CU20140127A7 (es) | Moduladores de la ruta del complemento y usos de los mismos | |
| CR20160175A (es) | Amino-heteroaril-benzamidas como inhibidores de cinasa | |
| UA100342U (ru) | Применение натриевой соли гидрогенсульфида как средства для снижения гастротоксичности нестероидных противовоспалительных средств | |
| CO7141426A2 (es) | Moduladores de la ruta del complemento y usos de los mismos |